Search
forLearn
5 / 801 resultslearn AHAs
learn Ceramide AP
learn zinc PCA
learn apple polyphenol
Research
5 / 176 resultsresearch 40nm, but not 750 or 1,500nm, Nanoparticles Enter Epidermal CD1a+ Cells after Transcutaneous Application on Human Skin
Only 40 nm nanoparticles can enter skin cells effectively for potential vaccine delivery.
research Nanoparticle-Based Targeting of Vaccine Compounds to Skin Antigen-Presenting Cells By Hair Follicles and their Transport in Mice
Nanoparticles can deliver vaccines through hair follicles, triggering immune responses and providing protection.
research Antigen presenting cells in the skin of a patient with hair loss and systemic lupus erythematosus.
Antigen presenting cells around hair follicles are crucial in SLE-related hair loss.
research Autolougous platelet concentrates in esthetic medicine
Autologous platelet concentrates show promise in esthetic treatments but need more standardized research.
research 976 Knockout of mTOR/Akt inhibitor REDD1 results in hair cycle-independent dermal adipose expansion by promoting adipocyte differentiation
Removing REDD1 in mice increases skin fat by making fat cells larger and more numerous.
Community Join
5 / 1000+ resultscommunity Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.